GLP-1 plays a key role in regulating blood sugar by stimulating insulin release and suppressing glucagon secretion
For a 250-pound patient, that represents approximately 56 pounds lost
However, despite their benefits, these medications have been linked to severe gastrointestinal issues, including gastroparesis and intestinal blockages
A separate 2024 meta-analysis in the journal Endocrine examining 29 trials with 26,985 participants with type 2 diabetes confirmed that semaglutide significantly reduced systolic blood pressure by about 2.31 mmHg compared to placebo or other antihyperglycemic agents
Youre not stuck at one level the whole time
The GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide sit behind the STEP (NEJM, 2021), SURMOUNT (NEJM, 2022), and SURMOUNT-OSA (NEJM, 2024) evidence, and the clinical picture does not change with the price tag